ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer Post author:admERY Post published:September 26, 2016 Post category:Newsroom ERYTECH Pharma today announced the final patient has been enrolled in its Phase 2 trial of eryaspase, also known as ERY-ASP or GRASPA®, for the treatment of pancreatic cancer. You Might Also Like ERYTECH announces ADR Level 1 listing in the US January 12, 2015 ERYTECH to Present Full Results for Phase 2b Trial of eryaspase in Pancreatic Cancer at ESMO 2017 August 31, 2017 ERYTECH Reports Third Quarter 2018 Financial Results and Provides Business Update November 12, 2018
ERYTECH to Present Full Results for Phase 2b Trial of eryaspase in Pancreatic Cancer at ESMO 2017 August 31, 2017